Table 1. Characteristics of Acute... | American Society of Hematology

Table 1.

Characteristics of Acute Leukemias With t(10;11)

No.	Sex/ Age (yr)	Leuko	Diagnosis	Induction Therapy	Resp	Survival (mos)		Immunophenotype				Karyotype	FISH
No.	Sex/ Age (yr)	Leuko	Diagnosis	Induction Therapy	Resp	EventFree	Overall	B-Cell	T-Cell	Myeloid	Other	Karyotype	AF10	CALM	MLL
1	M/51	60,800	AMLM5A	TAD-HAM	CR	14	15	CD19⁻	CD2⁻ CD4⁺ CD7⁺	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁽⁺⁾ CD34⁻ HLA-DR⁺ TDT⁻	46,XY, t(10;11)(p13;q14)	Split	N	Split
2	F/46	130,300	AMLM2	TAD-TAD	CR	15	19	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	48,XX, +6,+8, t(10;11)(p12-13;q14-21)	ND	N	Split
3	F/39	13,800	sec. AMLM2	TAD-HAM	ED	<1	<1	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁻ HLA-DR⁺ TDT⁻	45, X, −X, der(10)t(10;11)(p12-13;q13.1) inv(11)(q13.1q23.1), der(11)t(10;11)(p12-13;q13.1)	ND	N	Split
4	F/74	200	AMLM5	TAD-HAM^*	CR	2	14	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁽⁺⁾	46, XX, t(10;11;17)(p13;q13;q23)	ND	N	ND
5	F/37	4,000	AMLM1	TAD-HAM	CR	8	16	CD19⁻	CD2⁺ CD4⁻ CD7⁻	CD13⁺ CD14⁻ CD15⁺ CD33⁻ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	46, XX, der(10)t(10;11)(p12-13;q21) der(11)t(10;11;11;16) (p12-13;q21;p14-15;q13-22) del(11)(p13), del(12)(p11.2)	N	N	N
6	M/2	NA	AMLM5	AML-BFM87	NA	NA	5	CD19⁻	CD2⁻ CD4⁻ CD7⁻	CD13⁻ CD14⁻ CD15⁺ CD33⁺ CD65s⁺	CD10⁻ CD34⁻ HLA-DR⁺ TDT⁻	46, XY, t(10;11)(p12;q21)	Split	N	N
7	M/19	1,300	sec. AMLM1	TAD-HAM	ED	1	1	CD19⁻	CD2⁻ CD4⁻ CD7⁽⁺⁾	CD13⁽⁺⁾ CD14⁻ CD15⁻ CD33⁻ CD65s⁻	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	46, XY, t(10;11)(p13;q14)	Split	Split	N
8	M/47	20,000	AMLM0	T-ALL	ED	3	3	CD19⁻	CD3⁻	CD13⁺ CD33⁺	ND	48, XY, +3,add(7)(q33-35), der(9), der(9), +der(9), t(10;11)(p13;q21), der(12)t(12;18)(p11;q11), −18, +mar	Split	Split	N
9	F/21	60,800	AMLM1	TAD-HAM	CR	7	11	ND	ND	ND	ND	47, XX, +19, t(10;11)(p13-14;q14-21)	Split	Split	N
10	M/31	NA	T-ALL	CHOEP	NA	7	11	CD22⁻	CD1⁺ CD3⁺ CD4⁺ CD5⁺	CD11c⁻	CD10⁺ HLA-DR⁻	46, XY, del(7)(q34-q35), i(9)(q10), t(10;11)(p1?4;q14), der(17)t(1;17)(p13;p11)	ND	Split	N

No.	Sex/ Age (yr)	Leuko	Diagnosis	Induction Therapy	Resp	Survival (mos)		Immunophenotype				Karyotype	FISH
No.	Sex/ Age (yr)	Leuko	Diagnosis	Induction Therapy	Resp	EventFree	Overall	B-Cell	T-Cell	Myeloid	Other	Karyotype	AF10	CALM	MLL
1	M/51	60,800	AMLM5A	TAD-HAM	CR	14	15	CD19⁻	CD2⁻ CD4⁺ CD7⁺	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁽⁺⁾ CD34⁻ HLA-DR⁺ TDT⁻	46,XY, t(10;11)(p13;q14)	Split	N	Split
2	F/46	130,300	AMLM2	TAD-TAD	CR	15	19	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	48,XX, +6,+8, t(10;11)(p12-13;q14-21)	ND	N	Split
3	F/39	13,800	sec. AMLM2	TAD-HAM	ED	<1	<1	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁻ HLA-DR⁺ TDT⁻	45, X, −X, der(10)t(10;11)(p12-13;q13.1) inv(11)(q13.1q23.1), der(11)t(10;11)(p12-13;q13.1)	ND	N	Split
4	F/74	200	AMLM5	TAD-HAM^*	CR	2	14	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁽⁺⁾	46, XX, t(10;11;17)(p13;q13;q23)	ND	N	ND
5	F/37	4,000	AMLM1	TAD-HAM	CR	8	16	CD19⁻	CD2⁺ CD4⁻ CD7⁻	CD13⁺ CD14⁻ CD15⁺ CD33⁻ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	46, XX, der(10)t(10;11)(p12-13;q21) der(11)t(10;11;11;16) (p12-13;q21;p14-15;q13-22) del(11)(p13), del(12)(p11.2)	N	N	N
6	M/2	NA	AMLM5	AML-BFM87	NA	NA	5	CD19⁻	CD2⁻ CD4⁻ CD7⁻	CD13⁻ CD14⁻ CD15⁺ CD33⁺ CD65s⁺	CD10⁻ CD34⁻ HLA-DR⁺ TDT⁻	46, XY, t(10;11)(p12;q21)	Split	N	N
7	M/19	1,300	sec. AMLM1	TAD-HAM	ED	1	1	CD19⁻	CD2⁻ CD4⁻ CD7⁽⁺⁾	CD13⁽⁺⁾ CD14⁻ CD15⁻ CD33⁻ CD65s⁻	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	46, XY, t(10;11)(p13;q14)	Split	Split	N
8	M/47	20,000	AMLM0	T-ALL	ED	3	3	CD19⁻	CD3⁻	CD13⁺ CD33⁺	ND	48, XY, +3,add(7)(q33-35), der(9), der(9), +der(9), t(10;11)(p13;q21), der(12)t(12;18)(p11;q11), −18, +mar	Split	Split	N
9	F/21	60,800	AMLM1	TAD-HAM	CR	7	11	ND	ND	ND	ND	47, XX, +19, t(10;11)(p13-14;q14-21)	Split	Split	N
10	M/31	NA	T-ALL	CHOEP	NA	7	11	CD22⁻	CD1⁺ CD3⁺ CD4⁺ CD5⁺	CD11c⁻	CD10⁺ HLA-DR⁻	46, XY, del(7)(q34-q35), i(9)(q10), t(10;11)(p1?4;q14), der(17)t(1;17)(p13;p11)	ND	Split	N

Clinical, immunophenotypic, and cytogenetic characteristics and FISH results of acute leukemias (9 AML and 1 ALL) with t(10;11).

Abbreviations: Leuko, leukocytes per microliter at presentation; Resp, response; CR, complete response; ED, early death; NA, not available; (+), weakly positive; N, not split; ND, not done/evaluable (no material left for patients no. 4 and 10; poor sample quality for patients no. 2 and 3); ALL-BFM87, combined chemotherapy following the BFM87 protocol²⁰; T-ALL, intensified combined chemotherapy for adult T-cell lymphoblastic leukemia; CHOEP, combined chemotherapy (Cyclophosphamide/Adriamycin/Vincristin/Etoposide/Prednisolon).

*Reduced dose.

View Large

This Feature Is Available To Subscribers Only